CONTACT
+91 80 2808 2808
info@biocon.com

Biocon  /  Research Saves Lives

We are a leading contract research organisation that leverages collaborative science, to find better solutions for companies in the consumer, nutrition, agrochemicals and specialty sectors. Our purpose is to accelerate innovation and deliver solutions with efficiency, at world-class levels of quality and service.

A looming global pandemic, a massive spike in incidences of infectious diseases, rise in epidemics and chronic diseases, have patients seeking new & improved treatments from their healthcare providers. Healthcare experts the world over, rely entirely on advances in research to provide answers – whether its vaccines to eradicate life-threatening diseases like small pox or medication to help patients manage other illnesses. Researchers are fuelled by patient need and their passion for science to discover, develop and deliver breakthrough medicines. Syngene offers a diverse range of research services that help our clients realise their quest for new patient treatments. We understand that research saves lives.

Syngene is a well-established, trusted, strategic partner for life sciences companies around the world, across the drug discovery and development continuum. We are a leading contract research organisation that leverages collaborative science, to find better solutions for companies in the consumer, nutrition, agrochemicals and specialty sectors. Our purpose is to accelerate innovation and deliver solutions with efficiency, at world-class levels of quality and service.

Our state-of-the-art infrastructure, qualified team of scientists and rich expertise in emerging technologies, enable us to improve research and development productivity, drive innovation and reduce time-to-market for novel molecules. Through best-in-class infrastructure, tools, mentorship and funding, we provide the ideal platform for our scientists to innovate. Syngene’s competitive advantage stems from our ability to customise our scientific solutions.

Syngene’s business is divided into three units: dedicated research & development centers, discovery services and development & manufacturing services. Our dedicated research and development centers have infrastructure and scientific teams to suit the needs of individual clients. Discovery services include chemistry, biology, toxicology and bioinformatics services for both small and large molecules. Our development and manufacturing services involve pre-clinical studies, drug substance development, drug product development, allied services (stability services, viral testing, bioanalytical), clinical trials and manufacturing services for small molecules and biologics.

The tremendous rise of gene & cell therapies and growth in the field of immunotherapies, has made biologics a fast-growing space. This has boosted the growth opportunities for contract research and manufacturing organisations. As a specialised contract research organisation, with robust scientific capabilities, Syngene is committed to providing world-class, end-to-end solutions in the biologics space to develop and manufacture these complex and expensive drugs.

Our researchers are specialised in converting science into solutions that will serve patients. They help accelerate therapies for unmet medical needs and save patient lives. We invest in our scientific talent, infrastructure, processes, vendor management, logistics, supply chain and technology to widen our collaborations, drive growth and deliver value

Over the years, Syngene has nurtured long-term relationships with clients that help us deliver better value to all our stakeholders, by maximising efficiency and offering the benefit of cost savings. Our research strengths help expedite the path from discovery to commercialisation, enabling our partners to realise their goals faster. We align our research to our partners’ milestones. We leverage our strengths, scientific knowledge and technologies and combine it with that of our partners, to advance new therapies that can help patients.

Our-stories-847
Hope. Now within reach
novel-biologics-biocon-banner
Meeting unmet patient needs
diabetes-insulin-biocon-banner
The 10-c answer to diabetes
Share